News and information about DAMIAN and Primary Aldosteronism. 

At DAMIAN, we’re about passion, not convenience.

Teresa Gerlock
Chief Operating Officer
  • DAMIAN clinical plan affirmed by the Foundation for Therapeutic Research

    The Lausanne-based Foundation for Therapeutic Research awards a grant for the development of new therapeutic principles in cardiovascular disease to the University of Torino to investigate DP13. The grant supports the Phase I clinical trial of DP13, the first-in-class aldosterone synthase inhibitor from DAMIAN.

  • DAMIAN conducts Phase I study of DP13 

    DAMIAN executes its Phase I proof-of-concept, double-blind, safety and tolerability study of DP13 in healthy volunteers (NCT03046589). The Phase I study successfully completed in September 2018.

  • DAMIAN initiates Phase II study of DP13 

    DAMIAN enrolls the first patients in its multinational Phase II study of DP13 in patients with Primary Aldosteronism (NCT04007406; EUDRACT# 2019-000919-85).

  • DAMIAN receives research grant from Innosuisse (formerly CTI)

    Innosuisse awards second Swiss research grant to DAMIAN to support the further development of its diagnostic tool, DP14. The new funding follows the successful completion of the design phase and allows the team to execute the in vivo proof-of-concept experiments.

  • Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study

    This study by Hundemer et al. evaluated the electronic health records of PA patients on mineralocorticoid receptor antagonist (MRA) therapy and matched hypertensives to investigate the risk of cardiovascular events. The study demonstrated that in PA patients, the risks were higher than in patients with essential hypertension, independent of blood pressure control. The authors speculate that this may have to do, in part, with patients not responding adequately to MRA therapy.

    Hundemer et al., Lancet Diabetes Endocrinol. 2018 Jan;6(1):51-59; doi: 10.1016/S2213-8587(17)30367-4

  • Is primary aldosteronism still largely unrecognized?

    This review article highlights the disconnect between prospective, selective PA studies, which show a relatively high incidence rate, and real-world clinical data which demonstrate that PA remains under diagnosed and under treated. Diagnosis and referral rates remain low, despite the long-term risks associated with uncontrolled PA.

    Buffolo et al., Horm Metab Res. 2017;49:908-914; doi: 10.1055/s-0043-119755

  • Endocrine Society Guidelines for Primary Aldosteronism

    The Endocrine Society published an update to their clinical practice guidelines for management of patients with Primary Aldosteronism. These guidelines, based on data from systematic reviews and primary studies, provide an update to the recommendations of whom should be screened and the diagnostic pathway.

    J Clin Endocrinol Metab, May 2016, 101(5):1889 –1916; doi: 10.1210/jc.2015-4061